Hematology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Cutaneous Lymphoma Database

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to create a  long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions.

2. A Study of the Premier Hb9210TM Resolution System

   Rochester, Minn.

   The purpose of this study is to establish reference ranges for the Premier Hb210TM Resolution system in regard to hemoglobins A0, A2, and F for use in providing information for the comparative decision-making process in physiological assessment, medical diagnosis and therapeutic management of patients. 

3. P1101 in Treating Patients With Early Myelofibrosis

   Scottsdale/Phoenix, Ariz.

   This pilot phase II trial studies P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with early myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of early myelofibrosis.

4. A Study to Evaluate Gilteritinib vs. Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML.

    

5. CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma

   Scottsdale/Phoenix, Ariz.

   This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone. The study will consist of an escalating dose-escalation portion (Part 1) as well as an expansion of each cohort (ie, Cohort C: Monotherapy (MonoT) and Cohort D: Combination treatment with 2 drugs (DoubleT) at the recommended Phase 2 dose (RP2D) to further evaluate safety and estimate preliminary efficacy (Part 2).

6. Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

   Scottsdale/Phoenix, Ariz.

   This is a phase I, multicenter, open-label, dose-escalation study of BFCR4350A administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

7. A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

   Rochester, Minn.

   The purpose of this study is to evaluate the safety, pharmacokinetics, and preliminary effectiveness of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).

8. A Study to Determine the Effects of Activity by Ambulation in Hospital Premises versus Strict Protective Isolation on Quality of Life in Severely Neutropenic Cancer Patients during Hospitalization

   Jacksonville, Fla.

   The purpose of this study is to determine if allowing patients to ambulate in the hallways outside of their hospital room by relaxing the policy of strict protective isolation in neutropenic patients improves the quality of life, and if this increases the risk of infection among these patients during hospitalization.

9. A Study to Collect Data and Blood Samples from Mayo Patients Who have or are Suspected to have Amyloidosis, or Their Family Members, for Future Research

   Rochester, Minn.

   The purpose of this study is to create a data collection and bioregistry of blood samples from Mayo Clinic patients with amyloidosis, suspected amyloidosis, and family members of patients with amyloidosis. This information will be available for future research about this spectrum of diseases.

10. A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia

    Rochester, Minn.

    The purpose of this study is to evaluate the safety and effectiveness of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows:

    Stage 1: Enroll up to 14 participants and move to Stage 2 if 4 or more subjects meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment.

    Stage 2: Enroll up to an additional 23 participants with previously untreated or relapsed or refractory T-PLL.